{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:05:12Z","timestamp":1765609512008},"reference-count":60,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":380,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.jval.2012.02.012","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T17:02:46Z","timestamp":1339520566000},"page":"622-631","source":"Crossref","is-referenced-by-count":22,"title":["Cost-Effectiveness Analysis of the Bivalent Compared with the Quadrivalent Human Papillomavirus Vaccines in Taiwan"],"prefix":"10.1016","volume":"15","author":[{"given":"Nadia","family":"Demarteau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Hsiun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Chi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges","family":"Van Kriekinge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2012.02.012_bib1","series-title":"GLOBOCAN 2008 v1.2, cancer incidence and mortality worldwide: IARC Cancer Base No. 10 [Internet]","author":"Ferlay","year":"2010"},{"key":"10.1016\/j.jval.2012.02.012_bib2","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/jjco\/hyq057","article-title":"Cancer trends in Taiwan","volume":"40","author":"Chiang","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jval.2012.02.012_bib3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ijc.11222","article-title":"Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study","volume":"106","author":"Dalstein","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jval.2012.02.012_bib4","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/jnci\/djr283","article-title":"Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer","volume":"103","author":"Chen","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jval.2012.02.012_bib5","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/jnci\/djq356","article-title":"Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence","volume":"102","author":"Kjaer","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jval.2012.02.012_bib6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2012.02.012_bib7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"10.1016\/j.jval.2012.02.012_bib8","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1086\/590560","article-title":"Human papillomavirus genotype distribution in external acuminata condylomata: a large French national study (EDiTH IV)","volume":"47","author":"Aubin","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2012.02.012_bib9","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1055-9965.EPI-04-0812","article-title":"Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer","volume":"14","author":"Clifford","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jval.2012.02.012_bib10","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1086\/498164","article-title":"Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination","volume":"192","author":"Vandepapeliere","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jval.2012.02.012_bib11","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","year":"2007","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jval.2012.02.012_bib12","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2012.02.012_bib13","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2012.02.012_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Munoz","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jval.2012.02.012_bib15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.jval.2012.02.012_bib16","first-page":"1008","article-title":"Efficacy of the HPV-16\/18 AS04-adjuvanted vaccine against abnormal cytology and low-grade histopathological lesions in an oncogenic HPV-naive population","volume":"19","author":"Tjalma","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jval.2012.02.012_bib17","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jval.2012.02.012_bib18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2012.02.012_bib19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1517\/14712591003601944","article-title":"HPV vaccine: Cervarix","volume":"10","author":"Szarewski","year":"2010","journal-title":"Expert Opin Biol Ther"},{"issue":"Suppl. 5","key":"10.1016\/j.jval.2012.02.012_bib20","doi-asserted-by":"crossref","first-page":"F29","DOI":"10.1016\/j.vaccine.2008.05.069","article-title":"Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios","volume":"26","author":"Su\u00e1rez","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2012.02.012_bib21","series-title":"WHO Guide for Standardization of Economic Evaluations of Immunization Programmes: Final Version July 2008","year":"2008"},{"key":"10.1016\/j.jval.2012.02.012_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1472-6963-10-11","article-title":"Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan","volume":"10","author":"Liu","year":"2010","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jval.2012.02.012_bib23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/1471-2458-9-401","article-title":"A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females","volume":"9","author":"Anonychuk","year":"2009","journal-title":"BMC Public Health"},{"issue":"Suppl. 5","key":"10.1016\/j.jval.2012.02.012_bib24","doi-asserted-by":"crossref","first-page":"F16","DOI":"10.1016\/j.vaccine.2008.02.040","article-title":"Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination","volume":"26","author":"Debicki","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2012.02.012_bib25","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3111\/13696998.2010.490481","article-title":"Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer","volume":"13","author":"Demarteau","year":"2010","journal-title":"J Med Econ"},{"key":"10.1016\/j.jval.2012.02.012_bib28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejogrb.2008.03.014","article-title":"Type-specific distribution of HPV along the full spectrum of cervical carcinogenesis in Taiwan: an indication of viral oncogenic potential","volume":"140","author":"Ding","year":"2008","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jval.2012.02.012_bib29","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00404-009-1218-6","article-title":"Costs of cervical cancer and precancerous lesions treatment in a publicly financed health care system","volume":"281","author":"Tang","year":"2010","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.jval.2012.02.012_bib30","author":"Tsai"},{"issue":"Suppl. 1","key":"10.1016\/j.jval.2012.02.012_bib31","first-page":"S44","article-title":"Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan","volume":"13","author":"Koong","year":"2006","journal-title":"J Med Screen"},{"key":"10.1016\/j.jval.2012.02.012_bib32","first-page":"107","article-title":"Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France","volume":"35","author":"Monsonego","year":"2007","journal-title":"Gynecol Obstet Fertil"},{"key":"10.1016\/j.jval.2012.02.012_bib33","first-page":"485","article-title":"The natural history of type-specific human papillomavirus infections in female university students","volume":"12","author":"Richardson","year":"2003","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jval.2012.02.012_bib34","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00005650-199806000-00002","article-title":"Toward consistency in cost-utility analyses: using national measures to create condition-specific values","volume":"36","author":"Gold","year":"1998","journal-title":"Med Care"},{"key":"10.1016\/j.jval.2012.02.012_bib35","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/jnci\/djh104","article-title":"Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine","volume":"96","author":"Goldie","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jval.2012.02.012_bib36","series-title":"Health state transitions following an abnormal pap smear: implications for health utility assessment in cost-effectiveness analyses","author":"Insinga","year":"2005"},{"key":"10.1016\/j.jval.2012.02.012_bib37","series-title":"Vaccines for the 21st Century: A Tool for Decisionmaking","article-title":"Appendix 11: human papillomavirus","year":"2000"},{"key":"10.1016\/j.jval.2012.02.012_bib38","series-title":"Patient preferences for health states related to HPV infection: visual analog scale versus time trade-off elicitation","author":"Myers","year":"2004"},{"key":"10.1016\/j.jval.2012.02.012_bib39","first-page":"261","article-title":"Prevalence of cervical human papillomavirus in Taiwanese women","volume":"28","author":"Jeng","year":"2005","journal-title":"Clin Invest Med"},{"key":"10.1016\/j.jval.2012.02.012_bib40","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1001\/jama.285.23.2995","article-title":"Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females","volume":"285","author":"Moscicki","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2012.02.012_bib41","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/91.3.252","article-title":"Natural history of dysplasia of the uterine cervix","volume":"91","author":"Holowaty","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"4, Pt 2","key":"10.1016\/j.jval.2012.02.012_bib42","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0029-7844(98)00245-2","article-title":"Natural history of cervical squamous intraepithelial lesions: a meta-analysis","volume":"92","author":"Melnikow","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jval.2012.02.012_bib43","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/jnci\/djg037","article-title":"Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia","volume":"95","author":"Schlecht","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jval.2012.02.012_bib44","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1086\/315086","article-title":"Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer","volume":"180","author":"Franco","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jval.2012.02.012_bib45","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJM199802123380703","article-title":"Natural history of cervicovaginal papillomavirus infection in young women","volume":"338","author":"Ho","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2012.02.012_bib46","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/aje\/kwg171","article-title":"Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study","volume":"158","author":"Molano","year":"2003","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jval.2012.02.012_bib47","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/S0140-6736(01)06809-X","article-title":"Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear","volume":"358","author":"Nobbenhuis","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2012.02.012_bib48","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1001\/jama.286.24.3106","article-title":"Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia","volume":"286","author":"Schlecht","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2012.02.012_bib49","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/lgt.0b013e3180324114","article-title":"Midadult women's attitudes about receiving the prophylactic human papillomavirus vaccine","volume":"11","author":"Ferris","year":"2007","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.jval.2012.02.012_bib50","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.1016\/j.vaccine.2011.05.024","article-title":"HPV vaccination among a community sample of young adult women","volume":"29","author":"Manhart","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jval.2012.02.012_bib51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3201\/eid0901.020168","article-title":"Cost-effectiveness of a potential vaccine for human papillomavirus","volume":"9","author":"Sanders","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jval.2012.02.012_bib52","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/aje\/kwk059","article-title":"Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty","volume":"165","author":"Van De Velde","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jval.2012.02.012_bib54","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/oxfordjournals.aje.a117485","article-title":"Meta-analysis of Pap test accuracy","volume":"141","author":"Fahey","year":"1995","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jval.2012.02.012_bib55","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2012.02.012_bib56","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4067\/S0716-10182006000200010","article-title":"[Vaccines against papillomavirus infections and disease.]","volume":"23","author":"Villa","year":"2006","journal-title":"Rev Chilena Infectol"},{"key":"10.1016\/j.jval.2012.02.012_bib57","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4161\/hv.7.12.18281","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 vaccine and HPV-6\/11\/16\/18 vaccine: follow-up from months 12-24 in a phase III randomized study of healthy women aged 18\u201345 years","volume":"7","author":"Einstein","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.jval.2012.02.012_bib58","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1001\/jama.285.24.3107","article-title":"Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness","volume":"285","author":"Goldie","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2012.02.012_bib59","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1086\/597309","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16\u201326 Years","volume":"199","author":"Wheeler","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jval.2012.02.012_bib60","series-title":"HPV-16\/18 vaccine: sustained immunogenicity and efficacy up to 9.4 years","author":"Naud","year":"2011"},{"issue":"3, Suppl. 1","key":"10.1016\/j.jval.2012.02.012_bib61","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ygyno.2009.01.011","article-title":"Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses","volume":"115","author":"David","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jval.2012.02.012_bib62","first-page":"1551","article-title":"Burden of disease associated with cervical cancer in Malaysia and the potential costs and consequences of HPV vaccination","volume":"11","author":"Aljunid","year":"2010","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.jval.2012.02.012_bib63","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg Infect Dis"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301512000666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301512000666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T16:54:39Z","timestamp":1542905679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301512000666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S1098301512000666"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2012.02.012","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}